News About: Pharm. Industry
Court rules against Schering Plough in patent suit
Korea’s top court on Thursday dismissed claims by Schering Plough in a patent lawsuit against two local drug firms over their generic medicine Nasonex(mometasone nasal spray), a prescription nasal spray used to treat ...
Ildong forges strategic tie-up with Pfizer Korea
Ildong Pharmaceutical said yesterday that it has established a marketing and distribution partnership with Pfizer Korea.
Under the deal, Ildong will be in charge of selling Pfizer’s six products – five anticancer ...
Cialis will benefit from new indications
The Korea Food and Drug Administration said Monday that it has approved Eli Lilly's Cialis 5 mg to treat men with symptoms of BPH alone or with both benign prostatic hyperplasia (BPH) symptoms and erectile dysfunction...
Drug makers urged to bet on expensive medicines
Soaring research costs, rampant illicit rebates and a gushing inflow of multinational drug giants following free trade pacts have come together to ignite the biggest crisis in years in Korea’s pharmaceutical industry....
Zuellig Pharma still expanding
When Zuellig Pharma, a regional distributor of pharmaceutical and health care products, established a subsidiary in Korea in 2000, hundreds of local wholesalers went up in arms against the new entrant seeing it as a t...
Drug makers’ downsizing plan hits snag
The domestic drug industry has hit a snag with its plan to push employees to opt for early retirement plans amid growing worries over the lackluster earnings outlook, with most pharmaceutical firms reluctant to reduce...
Boehringer Ingelheim Animal Drug allegedly plotted union suppression schemes
Boehringer Ingelheim Animal Drug, a separate entity from Boehringer Ingelheim Korea, is under fire for allegedly suppressing the activity of its labor union.
The company is drawing protest from an employer surname...
Pharmaceutical firms’ sales forecast positive from 4Q
Local domestic companies’ sales are likely to regain their momentum from the fourth quarter thanks much to effects of new drugs launched during the January-March period, according to a local expert.
According to Ha...
Baraclude continues to thrive in the face of limited competition
The domestic hepatitis B market is still dominated by Baraclude (entecavir) with better efficacy and safety profiles and this trend likely to continue.
Developed by the US based Bristol-Myers Squibb, Baraclude does...
Local drug makers boosting R&D spending
Listed pharmaceutical firms have been spending more on research and development (R&D) projects to meet standards for the government support.
The Financial Supervisory Service (FSS) said Monday that the combined R&D...
